Literature DB >> 3162809

Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.

R R Bailey1, R J Walker, K L Lynn, I M Donaldson, B A Peddie, B R Dobbs.   

Abstract

1. Eight women with acute pyelonephritis were treated with i.v. enoxacin for 5 days. All were clinically cured and five had a bacteriological cure. Five women reported side effects. 2. During treatment there was no significant accumulation of enoxacin and the total clearance of the drug did not alter with repeated dosing. Drug elimination half-life (mean 4.3 h, s.d. 2.1) was similar to that reported in healthy volunteers. 3. Enoxacin should be compared with the aminoglycosides and beta-lactam antibiotics for the treatment of severe or complicated urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162809      PMCID: PMC1386477          DOI: 10.1111/j.1365-2125.1988.tb03294.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

2.  Enoxacin for the treatment of urinary tract infection.

Authors:  R R Bailey; B A Peddie
Journal:  N Z Med J       Date:  1985-04-24

3.  In vitro and in vivo antibacterial activity of AT-2266.

Authors:  K Kouno; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

4.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

5.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

  5 in total
  1 in total

Review 1.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.